Ozonated Sunflower Oil (OSO) Alleviates Inflammatory Responses in Oxazolone-Induced Atopic Dermatitis (AD)-Like Mice and LPS-Treated RAW 264.7 Cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Ozone, a highly reactive oxidant molecule, is widely used as a complementary therapy for various skin diseases, including wound healing, pressure ulcers, diabetic foot, and infections. However, there is limited research on the effectiveness of ozone for atopic dermatitis (AD). Ozonated sunflower oil (OSO) is an active ingredient obtained from partially ozonated sunflower oil (SO). OSO markedly reduced the LPS-induced increase in IL-1β and nitric oxide (NO) levels in RAW 264.7 mouse macrophage cells. Oxazolone (OXZ) was applied to hairless mice to induce AD-like skin symptoms and immune response. OSO significantly alleviated the OXZ-induced increases in the number of infiltrating mast cells, epidermal thickness, AD symptoms, thymic stromal lymphopoietin (TSLP), and filaggrin, as well as the serum levels of NO, IgE, IL-1β, and TNF-α. Furthermore, OSO inhibited the IL-4/STAT3/MAPK pathway and the expression of NF-κB. Our results suggest that OSO treatment could relieve AD-mediated skin damage through its anti-inflammatory and antioxidant activities. Therefore, it can be used as a therapeutic agent against AD-related skin diseases.
Abstract
Ozone, a highly reactive oxidant molecule, is widely used as a complementary therapy for various skin diseases, including wound healing, pressure ulcers, diabetic foot, and infections. However, there is limited research on the effectiveness of ozone for atopic dermatitis (AD). Ozonated sunflower oil (OSO) is an active ingredient obtained from partially ozonated sunflower oil (SO). OSO markedly reduced the LPS-induced increase in IL-1β and nitric oxide (NO) levels in RAW 264.7 mouse macrophage cells. Oxazolone (OXZ) was applied to hairless mice to induce AD-like skin symptoms and immune response. OSO significantly alleviated the OXZ-induced increases in the number of infiltrating mast cells, epidermal thickness, AD symptoms, thymic stromal lymphopoietin (TSLP), and filaggrin, as well as the serum levels of NO, IgE, IL-1β, and TNF-α. Furthermore, OSO inhibited the IL-4/STAT3/MAPK pathway and the expression of NF-κB. Our results suggest that OSO treatment could relieve AD-mediated skin damage through its anti-inflammatory and antioxidant activities. Therefore, it can be used as a therapeutic agent against AD-related skin diseases.
참고문헌 (47)
- Lee HJ, "Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis", Allergy Asthma Immunol. Res, 6, pp.276~287 (2014)
- Murota H, "Exacerbating factors and disease burden in patients with atopic dermatitis", Allergol. Int, 71, pp.25~30 (2022)
- Bylund S, "Prevalence and incidence of atopic dermatitis: a systematic review", Acta Derm. Venereol, 100, pp.adv00160~ (2020)
- Luger T, "Atopic dermatitis : role of the skin barrier, environment, microbiome, and therapeutic agents", J. Dermatol. Sci, 102, pp.142~157 (2021)
- Chovatiya R, "DESCRIBE-AD : a novel classification framework for atopic dermatitis", J. Am. Acad. Dermatol, 87, pp.541~550 (2022)
- Ingrid Böhm, "Th1-Zellen, Th2-Zellen und atopische dermatitis", Hautarzt, 48, pp.223~227 (1997)
- Kim YJ, "Topical administration of EGF suppresses immune response and protects skin barrier in DNCB-induced atopic dermatitis in NC", Nga mice, 2018, pp.8, 11895~
- Leung DYM, "Pathogenesis of atopic dermatitis", J. Allergy Clin. Immunol, 104 (1999)
- A Wollenberg, "Consensus-based European guidelines for treatment ofatopic eczema(atopic dermatitis)in adults and children : part I", JEADV, 32, pp.657~682 (2018)
- Ferreira S, "Selective JAK1 inhibitors for the treatment of atopic dermatitis : focus on upadacitinib and abrocitinib", Am. J. Clin. Dermatol, 21, pp.783~798 (2020)
- Simon D, "Systemic therapy for atopic dermatitis", Allergy, 69, pp.46~55 (2014)
- Kim BE, "Significance of skin barrier dysfunction in atopic dermatitis", Allergy Asthma Immunol. Res, 10, pp.207~215 (2018)
- Drislane C, "The role of filaggrin in atopic dermatitis and allergic disease", Ann. Allergy Asthma Immunol, 124, pp.36~43 (2020)
- Osawa R, "Filaggrin gene defects and the risk of developing allergic disorders", Allergol. Int, 60, pp.1~9 (2011)
- Zaniboni MC, "Skin barrier in atopic dermatitis : beyond filaggrin", An. Bras. Dermatol, 91, pp.472~478 (2016)
- Kim JH, "Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3(STAT3)and extracellular signal-regulated kinase(ERK)phosphorylation in keratinocytes", J. Allergy Clin. Immunol, 136, pp.205~208 (2015)
- Liu L, "Ozone therapy for skin diseases : cellular and molecular mechanisms", Int. Wound J, 20, pp.2376~2385 (2023)
- Di Mauro R, "The biochemical and pharmacological properties of ozone : the smell of protection in acute and chronic diseases", Int. J. Mol. Sci, 20, pp.634~ (2019)
- Wen Q, "A systematic review of ozone therapy for treating chronically refractory wounds and ulcers", Int. Wound J, 19, pp.853~870 (2022)
- Zeng J, "Topical ozone therapy restores microbiome diversity in atopic dermatitis", Int. Immunopharmacol, 80, pp.106191~ (2020)
- Zeng J, "Ozone therapy attenuates NF-kappaB-mediated local inflammatory response and activation of Th17 cells in treatment for psoriasis", Int. J. Biol. Sci, 16, pp.1833~1845 (2020)
- Raghad Abdulsalam Khaleel, "POSSIBLE PROTECTIVE EFFECT OF OZONE THERAPY IN IMIQUIMOD INDUCED PSORIASIS-LIKE INFLAMMATION IN MICE", HIV Nursing, 22, pp.809~813 (2022)
- Cho KH, "Ozonated sunflower oil exerted protective effect for embryo and cell survival via potent reduction power and antioxidant activity in HDL with strong antimicrobial activity", Antioxidants(Basel), 10, pp.1651~ (2021)
- Menendez S, "Therapeutic efficacy of topical OLEOZON(R)in patients suffering from onychomycosis", Mycoses, 54, pp.e272~e277 (2011)
- Man MQ, "Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis : structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges", J. Invest. Dermatol, 128, pp.79~86 (2008)
- Sharma JN, "Role of nitric oxide in inflammatory diseases", Inflammopharmacology, 15, pp.252~259 (2007)
- Lopez-Castejon G, "Understanding the mechanism of IL-1beta secretion", Cytokine Growth Factor Rev, 22, pp.189~195 (2011)
- Nathan C, "Nitric oxide as a secretory product of mammalian cells", FASEB J, 6, pp.3051~3064 (1992)
- Angelika Bierhaus, "Diabetesassociated sustained activation of the transcription factor nuclear factor-B", Diabetes, 50, pp.2792~2808 (2001)
- Yoshiyuki Hattori, "High-glucose-induced nuclear factor kB activation in vascular smooth muscle cells", Cardiovasc. Res, 46, pp.188~197 (2000)
- Ogawa T, "NRF2 Augments epidermal antioxidant defenses and promotes atopy", J. Immunol, 205, pp.907~914 (2020)
- Nakashima C, "Innovation in the treatment of atopic dermatitis : emerging topical and oral Janus kinase inhibitors", Allergol. Int, 71, pp.40~46 (2022)
- Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP", Nat. Immunol, 3, pp.673~680 (2002)
- Sano Y, "Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis", Clin. Exp. Immunol, 171, pp.330~337 (2013)
- Banerjee S, "JAK-STAT signaling as a target for inflammatory and autoimmune diseases : current and future prospects", Drugs, 77, pp.521~546 (2017)
- Boengler K, "The myocardial JAK", STAT pathway : from protection to failure, 2008, pp.120, 172~185
- Bao L, "IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2", Stat6 signal transduction pathway : implication for atopic dermatitis, 2012, pp.50, 91~97
- Furue M, "Regulation of skin barrier function via competition between AHR axis versus IL-13", IL-4-JAK-STAT6, J. Clin. Med, pp.2020, 9[DOI]
- Dai X, "TSLP Impairs epidermal barrier integrity by stimulating the formation of nuclear IL-33", phosphorylated STAT3 complex in human keratinocytes, 2022, pp.142, 2100~2108
- Sies H, "Oxidative stress", Annu. Rev. Biochem, 86, pp.715~748 (2017)
- Longjam Shantabi, "Antioxidant properties of croton caudatus leaf extract in vitro", Transl. Med. Biotech, 2 (2014)
- Rotti RB, "Green synthesis of MgO nanoparticles and its antibacterial properties", Front. Chem, 11, pp.1143614~ (2023)
- Ji H, "Oxidative stress in atopic dermatitis", Oxid. Med. Cell. Longev, 2016, pp.2721469~ (2016)
- Scassellati C, "Molecular mechanisms in cognitive frailty : potential therapeutic targets for oxygen-ozone treatment", Mech. Ageing Dev, 186, pp.111210~ (2020)
- Wang Y, "The role of IL-1beta and TNF-alpha in intervertebral disc degeneration", Biomed. Pharmacother, 131, pp.110660~ (2020)
- Schafer M, "Nrf2 establishes a glutathione-mediated gradient of UVB cytoprotection in the epidermis", Genes Dev, 24, pp.1045~1058 (2010)
- Weidinger S, "Atopic dermatitis", Nat. Rev. Dis. Primers, 4, pp.1~ (2018)